A multi-center randomized controlled trial to evaluate efficacy and safety of early conversion to a low-dose calcineurin inhibitor combined with sirolimus in renal transplant patients

Author:

Zheng Xiang1,Zhang Weijie2,Zhou Hua3,Cao Ronghua4,Shou Zhangfei5,Zhang Shuwei6,Cheng Ying7,Chen Xuchun7,Ding Chenguang8,Li Ning3,Shi Shaohua3,Zhou Qiang9,Chen Qiuyuan4,Chen Gang4,Chen Zheng10,Zhou Peijun11,Hu Xiaopeng1,Xue Wujun8,Zhang Xiaodong1,Na Ning12,Wang Wei1

Affiliation:

1. Department of Urology, Capital Medical University Beijing Chaoyang Hospital, Beijing 100020, China

2. Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430032, China

3. Kidney Transplantation Dialysis Center, The Second People's Hospital of Shanxi Province, Taiyuan, Shanxi 030012, China

4. Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong 510120, China

5. Department of Nephrology, Shulan (Hangzhou) Hospital, Hangzhou, Zhejiang 310000, China

6. Department of Urology, Ningbo Yinzhou Number. 2 Hospital, Ningbo, Zhejiang 315000, China

7. Department of Organ Transplantation, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, China

8. Institute of Kidney Transplantation, The First Affiliated Hospital, Medical College of Xi’an Jiaotong University, Xi’an, Shaanxi 710061, China

9. Kidney Department, Southwest Hospital, The First Hospital Affiliated to The Third Military Medical University (Army Medical University), Chongqing 400000, China

10. Organ Transplant Center, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510260, China

11. Department of Urology, Kidney Transplantation Center, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200000, China

12. Department of Urology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, China.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3